FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100453931> ?p ?o ?g. }

• W3100453931 endingPage "2170" @default.
• W3100453931 startingPage "2161" @default.
• W3100453931 abstract "Peripheral T-cell lymphomas (PTCLs) are uniquely vulnerable to epigenetic modifiers. We demonstrated in vitro synergism between histone deacetylase inhibitors and DNA methyltransferase inhibitors in preclinical models of T-cell lymphoma. In a phase 1 trial, we found oral 5-azacytidine and romidepsin to be safe and effective, with lineage-selective activity among patients with relapsed/refractory (R/R) PTCL. Patients who were treatment naïve or who had R/R PTCL received azacytidine 300 mg once per day on days 1 to 14, and romidepsin 14 mg/m2 on days 8, 15, and 22 every 35 days. The primary objective was overall response rate (ORR). Targeted next-generation sequencing was performed on tumor samples to correlate mutational profiles and response. Among 25 enrolled patients, the ORR and complete response rates were 61% and 48%, respectively. However, patients with T-follicular helper cell (tTFH) phenotype exhibited higher ORR (80%) and complete remission rate (67%). The most frequent grade 3 to 4 adverse events were thrombocytopenia (48%), neutropenia (40%), lymphopenia (32%), and anemia (16%). At a median follow-up of 13.5 months, the median progression-free survival, duration of response, and overall survival were 8.0 months, 20.3 months, and not reached, respectively. The median progression-free survival and overall survival were 8.0 months and 20.6 months, respectively, in patients with R/R disease. Patients with tTFH enjoyed a particularly long median survival (median not reached). Responders harbored a higher average number of mutations in genes involved in DNA methylation and histone deacetylation. Combined azacytidine and romidepsin are highly active in PTCL patients and could serve as a platform for novel regimens in this disease. This trial was registered at www.clinicaltrials.gov as #NCT01998035." @default.
• W3100453931 created "2020-11-23" @default.
• W3100453931 creator A5002126535 @default.
• W3100453931 creator A5005238069 @default.
• W3100453931 creator A5008185510 @default.
• W3100453931 creator A5013791965 @default.
• W3100453931 creator A5014966517 @default.
• W3100453931 creator A5016848239 @default.
• W3100453931 creator A5021276677 @default.
• W3100453931 creator A5025493803 @default.
• W3100453931 creator A5028291843 @default.
• W3100453931 creator A5029409714 @default.
• W3100453931 creator A5032180638 @default.
• W3100453931 creator A5037214066 @default.
• W3100453931 creator A5044149196 @default.
• W3100453931 creator A5044899339 @default.
• W3100453931 creator A5044954469 @default.
• W3100453931 creator A5050980011 @default.
• W3100453931 creator A5055822207 @default.
• W3100453931 creator A5059661907 @default.
• W3100453931 creator A5068579618 @default.
• W3100453931 creator A5083260275 @default.
• W3100453931 creator A5090759974 @default.
• W3100453931 date "2021-04-22" @default.
• W3100453931 modified "2023-10-17" @default.
• W3100453931 title "Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study" @default.
• W3100453931 cites W1522186213 @default.
• W3100453931 cites W2028078153 @default.
• W3100453931 cites W2036832665 @default.
• W3100453931 cites W2044060805 @default.
• W3100453931 cites W2069271377 @default.
• W3100453931 cites W2071115015 @default.
• W3100453931 cites W2074678620 @default.
• W3100453931 cites W2080029028 @default.
• W3100453931 cites W2088734399 @default.
• W3100453931 cites W2109716912 @default.
• W3100453931 cites W2133201432 @default.
• W3100453931 cites W2146146853 @default.
• W3100453931 cites W2168639163 @default.
• W3100453931 cites W2171873783 @default.
• W3100453931 cites W2275197865 @default.
• W3100453931 cites W2618698082 @default.
• W3100453931 cites W2894682501 @default.
• W3100453931 cites W2915806106 @default.
• W3100453931 cites W2970510348 @default.
• W3100453931 cites W2979660885 @default.
• W3100453931 cites W4233431843 @default.
• W3100453931 doi "https://doi.org/10.1182/blood.2020009004" @default.
• W3100453931 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33171487" @default.
• W3100453931 hasPublicationYear "2021" @default.
• W3100453931 type Work @default.
• W3100453931 sameAs 3100453931 @default.
• W3100453931 citedByCount "75" @default.
• W3100453931 countsByYear W31004539312021 @default.
• W3100453931 countsByYear W31004539312022 @default.
• W3100453931 countsByYear W31004539312023 @default.
• W3100453931 crossrefType "journal-article" @default.
• W3100453931 hasAuthorship W3100453931A5002126535 @default.
• W3100453931 hasAuthorship W3100453931A5005238069 @default.
• W3100453931 hasAuthorship W3100453931A5008185510 @default.
• W3100453931 hasAuthorship W3100453931A5013791965 @default.
• W3100453931 hasAuthorship W3100453931A5014966517 @default.
• W3100453931 hasAuthorship W3100453931A5016848239 @default.
• W3100453931 hasAuthorship W3100453931A5021276677 @default.
• W3100453931 hasAuthorship W3100453931A5025493803 @default.
• W3100453931 hasAuthorship W3100453931A5028291843 @default.
• W3100453931 hasAuthorship W3100453931A5029409714 @default.
• W3100453931 hasAuthorship W3100453931A5032180638 @default.
• W3100453931 hasAuthorship W3100453931A5037214066 @default.
• W3100453931 hasAuthorship W3100453931A5044149196 @default.
• W3100453931 hasAuthorship W3100453931A5044899339 @default.
• W3100453931 hasAuthorship W3100453931A5044954469 @default.
• W3100453931 hasAuthorship W3100453931A5050980011 @default.
• W3100453931 hasAuthorship W3100453931A5055822207 @default.
• W3100453931 hasAuthorship W3100453931A5059661907 @default.
• W3100453931 hasAuthorship W3100453931A5068579618 @default.
• W3100453931 hasAuthorship W3100453931A5083260275 @default.
• W3100453931 hasAuthorship W3100453931A5090759974 @default.
• W3100453931 hasBestOaLocation W31004539311 @default.
• W3100453931 hasConcept C104317684 @default.
• W3100453931 hasConcept C126322002 @default.
• W3100453931 hasConcept C143998085 @default.
• W3100453931 hasConcept C150194340 @default.
• W3100453931 hasConcept C190727270 @default.
• W3100453931 hasConcept C197934379 @default.
• W3100453931 hasConcept C203014093 @default.
• W3100453931 hasConcept C2776090121 @default.
• W3100453931 hasConcept C2776239401 @default.
• W3100453931 hasConcept C2776694085 @default.
• W3100453931 hasConcept C2777063308 @default.
• W3100453931 hasConcept C2777891184 @default.
• W3100453931 hasConcept C2778305200 @default.
• W3100453931 hasConcept C2779338263 @default.
• W3100453931 hasConcept C2780225316 @default.
• W3100453931 hasConcept C2780235182 @default.
• W3100453931 hasConcept C2780739268 @default.
• W3100453931 hasConcept C2780873365 @default.
• W3100453931 hasConcept C2781462825 @default.

• next